{"prompt": "['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 4 of 51', 'Study ID RCB: 2020-A00652-37', '1', 'Table of Contents', '1 Table of Contents', '4', '2 List of Abbreviations', '7', '3 Responsible Parties', '8', '4 Abstract', '10', '5 Amendments and Updates', '15', '6 Milestones', '16', '7 Rationale and Background', '16', '8 Research Question and Objectives', '20', '8.1 Primary Objective', '20', '8.2 Secondary Objectives', '20', '9 Research Method', '20', '9.1', 'Study Design', '20', '9.1.1', 'Eligibility criteria', '20', '9.1.2', 'PSO-TARGET Quality of Life Component grid.', '21', '9.1.3', 'Dermatology Quality of Life Index (DLQI)', '22', '9.1.4', 'Limitation of bias', '23', '9.1.5', 'Study Schedule', '23', '9.1.6', 'Definition of a non-interventional study', '24', '9.2 Setting', '25', '9.3 Variables', '26', '9.4', 'Data Source', '28', '9.5', 'Study Size', '29', '9.6 Data Management', '30', '9.7', 'Data Analysis', '32', '9.8', 'Statistical Analysis Plan', '32', '9.8.1', 'Description of the population', '32', '9.8.2', 'Baseline characteristics', '33', '9.8.3', 'Sensitivity/sensibility analysis', '33', '9.8.4', 'Efficacy analysis', '35', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 5 of 51', 'Study ID RCB: 2020-A00652-37', '9.8.5', 'Other secondary analyses', '36', '9.8.6', 'Safety analysis', '39', '9.9', 'Quality Control', '39', '9.9.1', 'Data Collection', '39', '9.9.2', 'Data monitoring', '39', '9.9.3', 'Data validation', '40', '9.10 Limitations of Research Methods', '40', '9.11 Other Aspects', '41', '10 Protection of human subjects', '41', '11 Management and Reporting of Adverse Events and Other Experiences', '44', '11.1 Definitions', '44', \"11.2 Physician's responsibility for reporting of Adverse Drug Reactions, Adverse Events and\", 'Other Experiences', '45', '11.3 LEO responsibilities for reporting of safety-related data', '47', '12 Plans for Disseminating and Communicating Study Results', '47', '13 References', '48', 'Annex 1. PSO-TARGET Component Grid', '51', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']['NIS-PSO-TARGET', 'Non-Interventional Study Protocol', 'Page 6 of 51', 'Study ID RCB: 2020-A00652-37', 'APPENDICES', '1.', 'PSO-TARGET Component grid', 'THIS DOCUMENT CONTAINS TRADE SECRETS, AND/OR COMMERCIAL OR FINANCIAL INFORMATION, PRIVILEGED OR CONFIDENTIAL. DELI-', 'VERED IN CONFIDENCE AND RELIANCE THAT SUCH INFORMATION WILL NOT BE COPIED OR MADE AVAILABLE TO ANY THIRD PARTY', 'WITHOUT THE WRITTEN CONSENT OF LEO PHARMA A/S']\n\n###\n\n", "completion": "END"}